Suppr超能文献

长链非编码RNA XIST和MALAT1在乳腺癌亚型中劫持PD-L1调控信号通路。

Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes.

作者信息

Samir Amany, Tawab Reda Abdel, El Tayebi Hend M

机构信息

Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, German University in Cairo, Cairo 11835, Egypt.

Department of General Surgery, Ain Shams University, Cairo 11772, Egypt.

出版信息

Oncol Lett. 2021 Aug;22(2):593. doi: 10.3892/ol.2021.12854. Epub 2021 Jun 7.

Abstract

Long non-coding RNAs (lncRNAs) have attracted widespread attention as potential biological and pathological regulators. lncRNAs are involved in several biological processes in cancer. Triple negative breast cancer (TNBC) is characterized by strong heterogeneity and aggressiveness. At present, the implication of microRNAs (miRs) and lncRNAs in immunotherapy has been poorly studied. Nevertheless, the blockade of immune checkpoints, particularly that of the programmed cell-death protein-1/programmed cell-death ligand-1 (PD-L1) axis, is considered as a principle approach in breast cancer (BC) therapy. The present study aimed to investigate the interaction between immune-modulatory upstream signaling pathways of the PD-L1 transcript that could enhance personalized targeted therapy. MDA-MB-231 cells were transfected with miR-182-5p mimics followed by RNA extraction and cDNA synthesis using a reverse transcription kit, and the expression levels of the target genes were assessed by reverse transcription-quantitative PCR. Furthermore, the expression levels of target genes were measured in tissues derived from 41 patients with BC, including patients with luminal BC and TNBC, as well as their adjacent lymph nodes. The results revealed that the expression levels of miR-182-5p, PD-L1 and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) were upregulated in MDA-MB-231 cells and BC tissues. However, X-inactive specific transcript (XIST) expression was downregulated in cancer tissues and TNBC cells. Following co-transfection of cells with small interfering RNAs specific for each target gene and miR-182-5p antagomirs, the effect of miR-182-5p was abolished in the presence of lncRNAs. Therefore, the results of the present study indicated that although miR-182-5p exhibited an oncogenic effect, XIST exerted a dominant effect on the regulation of the PD-L1 signaling pathway via the inhibition of the oncogenic function of MALAT1.

摘要

长链非编码RNA(lncRNAs)作为潜在的生物和病理调节因子已引起广泛关注。lncRNAs参与癌症的多个生物学过程。三阴性乳腺癌(TNBC)具有高度异质性和侵袭性。目前,微小RNA(miRs)和lncRNAs在免疫治疗中的作用研究较少。然而,免疫检查点阻断,特别是程序性细胞死亡蛋白1/程序性细胞死亡配体1(PD-L1)轴的阻断,被认为是乳腺癌(BC)治疗的主要方法。本研究旨在探讨可增强个性化靶向治疗的PD-L1转录本免疫调节上游信号通路之间的相互作用。用miR-182-5p模拟物转染MDA-MB-231细胞,随后使用逆转录试剂盒进行RNA提取和cDNA合成,并通过逆转录定量PCR评估靶基因的表达水平。此外,还测量了41例BC患者(包括管腔型BC和TNBC患者)及其相邻淋巴结组织中靶基因的表达水平。结果显示,miR-182-5p、PD-L1和转移相关肺腺癌转录本1(MALAT1)在MDA-MB-231细胞和BC组织中的表达水平上调。然而,X染色体失活特异性转录本(XIST)在癌组织和TNBC细胞中的表达下调。在用针对每个靶基因的小干扰RNA和miR-182-5p拮抗剂共转染细胞后,在lncRNAs存在的情况下,miR-182-5p的作用被消除。因此,本研究结果表明,尽管miR-182-5p具有致癌作用,但XIST通过抑制MALAT1的致癌功能对PD-L1信号通路的调节发挥主导作用。

相似文献

1
Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes.
Oncol Lett. 2021 Aug;22(2):593. doi: 10.3892/ol.2021.12854. Epub 2021 Jun 7.
3
4
Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
Pathol Res Pract. 2023 Aug;248:154579. doi: 10.1016/j.prp.2023.154579. Epub 2023 May 29.
6
MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer.
Transl Oncol. 2023 May;31:101653. doi: 10.1016/j.tranon.2023.101653. Epub 2023 Mar 11.
8
Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer.
Biomed Pharmacother. 2017 Nov;95:922-928. doi: 10.1016/j.biopha.2017.09.005. Epub 2017 Sep 12.
9
XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.
Front Oncol. 2020 Jan 10;9:1459. doi: 10.3389/fonc.2019.01459. eCollection 2019.

引用本文的文献

2
The multiple functions and mechanisms of long non-coding RNAs in regulating breast cancer progression.
Front Pharmacol. 2025 Mar 28;16:1559408. doi: 10.3389/fphar.2025.1559408. eCollection 2025.
3
Potential therapies for non-coding RNAs in breast cancer.
Front Oncol. 2024 Sep 20;14:1452666. doi: 10.3389/fonc.2024.1452666. eCollection 2024.
4
Roles of lncRNA in the diagnosis and prognosis of triple-negative breast cancer.
J Zhejiang Univ Sci B. 2023 Dec 15;24(12):1123-1140. doi: 10.1631/jzus.B2300067.
5
PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
Cancers (Basel). 2023 Sep 22;15(19):4682. doi: 10.3390/cancers15194682.
6
MALAT1 Long Non-coding RNA and Its Role in Breast Carcinogenesis.
Acta Naturae. 2023 Apr-Jun;15(2):32-41. doi: 10.32607/actanaturae.11905.
7
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.
Genes Dis. 2022 Aug 24;10(4):1318-1350. doi: 10.1016/j.gendis.2022.07.024. eCollection 2023 Jul.
8
The current advances of lncRNAs in breast cancer immunobiology research.
Front Immunol. 2023 Jun 5;14:1194300. doi: 10.3389/fimmu.2023.1194300. eCollection 2023.
9
LINC00426 is a potential immune phenotype-related biomarker and an overall survival predictor in PAM50 luminal B breast cancer.
Front Genet. 2023 May 16;14:1034569. doi: 10.3389/fgene.2023.1034569. eCollection 2023.
10
Potential roles of lncRNA-XIST/miRNAs/mRNAs in human cancer cells.
Clin Transl Oncol. 2023 Jul;25(7):2015-2042. doi: 10.1007/s12094-023-03110-y. Epub 2023 Feb 28.

本文引用的文献

3
XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.
Front Oncol. 2020 Jan 10;9:1459. doi: 10.3389/fonc.2019.01459. eCollection 2019.
4
lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer.
Breast Cancer. 2020 Jul;27(4):573-585. doi: 10.1007/s12282-020-01048-5. Epub 2020 Jan 20.
5
MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer.
J Cancer Res Ther. 2019;15(7):1597-1602. doi: 10.4103/jcrt.JCRT_282_19.
6
Long non-coding RNA XIST promotes hepatocellular carcinoma progression by sponging miR-200b-3p.
Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9857-9862. doi: 10.26355/eurrev_201911_19549.
7
X Inactivation and Escape: Epigenetic and Structural Features.
Front Cell Dev Biol. 2019 Oct 1;7:219. doi: 10.3389/fcell.2019.00219. eCollection 2019.
8
Long non-coding RNA XIST promotes cell proliferation and migration through targeting miR-133a in bladder cancer.
Exp Ther Med. 2019 Nov;18(5):3475-3483. doi: 10.3892/etm.2019.7960. Epub 2019 Aug 29.
10
Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas.
Bosn J Basic Med Sci. 2020 Feb 5;20(1):63-69. doi: 10.17305/bjbms.2019.4297.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验